COMBINED ORAL ISOPRINOSINE INTRAVENTRICULAR ALPHA-INTERFERON THERAPY FOR SUBACUTE SCLEROSING PANENCEPHALITIS
COMBINED ORAL ISOPRINOSINE INTRAVENTRICULAR ALPHA-INTERFERON THERAPY FOR SUBACUTE SCLEROSING PANENCEPHALITIS
复制标题
DOI：
10.1016/0387-7604(93)90120-w
复制
发表时间：
1993-09-01
影响因子：
1.7
通讯作者：
JALLU, A
中科院分区：
文献类型：
--
作者：
GASCON, G;YAMANI, S;JALLU, A
用口服异丙肌苷（100 mg/kg/天）和脑室内α-干扰素2b（Intron A，Schering Corp.）治疗18名患有亚急性硬化性全脑炎（SSPE）的患者，16名男孩和2名女孩，年龄5-14岁，从每周两次50万U开始，后来增加到每两周300万U。存活患者的最短随访时间为12个月，最长为40个月。根据神经功能障碍指数（NDI）评分和分期，8例治疗诱导缓解（3例改善，5例停滞），4例恶化，6例死亡。这44%（8/18）的缓解/改善率与同一机构历史对照的9%（1/11）缓解率相比（p = 0.001）。
Eighteen patients, 16 boys and 2 girls, aged 5-14 years, with subacute sclerosing panencephalitis (SSPE) were treated with oral isoprinosine (100 mg/kg/day) and intraventricular alpha-interferon 2b (Intron A, Schering Corp.), starting at 500,000 U twice a week and later increasing to 3 million U biweekly. Minimal follow-up of living patients is 12 months; maximal 40 months. On the basis of the Neurological Disability Index (NDI) scores and staging, 8 have treatment-induced remissions (3 improved, 5 arrested), 4 are worse and 6 died. This 44% (8/18) rate of remission/improvement compares well with the 9% (1/11) remission in historical controls in the same institution (p =